Artwork

InnehÄll tillhandahÄllet av Jon Chee. Allt poddinnehÄll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahÄlls direkt av Jon Chee eller deras podcastplattformspartner. Om du tror att nÄgon anvÀnder ditt upphovsrÀttsskyddade verk utan din tillÄtelse kan du följa processen som beskrivs hÀr https://sv.player.fm/legal.
Player FM - Podcast-app
GĂ„ offline med appen Player FM !

🧬 Terry Lo - Vizgen - Part 2 | Terry’s Move from Big Pharma to Diagnostics | Introduction to Spatial Biology | Navigating Regulatory & Reimbursement Challenges in Diagnostics | Balancing Multiple Roles in M&A Negotiations

30:18
 
Dela
 

Manage episode 411740915 series 3461709
InnehÄll tillhandahÄllet av Jon Chee. Allt poddinnehÄll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahÄlls direkt av Jon Chee eller deras podcastplattformspartner. Om du tror att nÄgon anvÀnder ditt upphovsrÀttsskyddade verk utan din tillÄtelse kan du följa processen som beskrivs hÀr https://sv.player.fm/legal.
Part 2 of 3.
As a podcast listener, you can redeem exclusive discounts with a growing list of biotech vendors and get $500 off your first equipment lease by using promo code “TBSP” on https://www.excedr.com/rewards.

My guest for this week’s episode is Terry Lo, President and CEO of Vizgen. Vizgen is developing and commercializing the next generation of genomics tools to expand on the capabilities of spatially resolved transcriptomics.

Terry is a pioneer in the emerging Spatial Biology market, with a proven track record of driving exceptional growth across global life science organizations, including Bristol-Myers Squibb, Roche, Hologic, and PerkinElmer. In addition to his two decades of experience scaling and building multinational biopharma and diagnostic groups, he is also an expert in developing business strategies for novel, innovative products.

Join us for part 2 of our conversation with Terry, where we talk about his transition from Big Pharma to diagnostics, the challenges of moving into the diagnostics industry, and the contrasts between drug and diagnostic development processes. Terry also discusses his experience at Roche, his time with Akoya Biosciences after PerkinElmer, and his involvement in the M&A process while balancing multiple roles. Please enjoy my conversation with Terry Lo.
Find Our Guest, Terry Lo, at these links:

Find Our Host, Jon Chee, at these links:

Timestamps:
00:28 Intro
01:35 Leaving Bristol, joining Cytyc, and transitioning into International Strategy role
03:48 The contrasts between Diagnostics and Big Pharma
05:28 Drug development vs. diagnostics development processes
09:27 Moving to China and adapting to his role change from International Strategy to Managing Director
10:43 Adjusting to life in China with his pregnant wife
13:25 Moving back to the US and joining Roche Molecular in California
15:26 Transitioning to PerkinElmer and Terry’s intro to spatial biology
17:28 The challenges and triumphs in this new field
20:25 The challenges of regulatory agencies and reimbursement in Diagnostics and getting a product through the FDA
24:58 Merging with Akoya Biosciences after PerkinElmer to support Terry’s platform
26:51 Terry’s experience with M&A of Akoya by PerkinElmer, balancing multiple roles
29:13 Outro ​

Social & Website:

Topics Mentioned:
Drug development vs. diagnostics development https://www.ncbi.nlm.nih.gov/books/NBK235489/
How Biotech & Big Pharma Partner to Support R&D https://www.excedr.com/blog/how-biotech-partnerships-support-research
Regulatory and reimbursement impacts in Pharma https://www.ncbi.nlm.nih.gov/books/NBK234312/
Drug approval with FDA
The Biotech Startups Podcast is handcrafted by our friends over at: fame.so
  continue reading

76 episoder

Artwork
iconDela
 
Manage episode 411740915 series 3461709
InnehÄll tillhandahÄllet av Jon Chee. Allt poddinnehÄll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahÄlls direkt av Jon Chee eller deras podcastplattformspartner. Om du tror att nÄgon anvÀnder ditt upphovsrÀttsskyddade verk utan din tillÄtelse kan du följa processen som beskrivs hÀr https://sv.player.fm/legal.
Part 2 of 3.
As a podcast listener, you can redeem exclusive discounts with a growing list of biotech vendors and get $500 off your first equipment lease by using promo code “TBSP” on https://www.excedr.com/rewards.

My guest for this week’s episode is Terry Lo, President and CEO of Vizgen. Vizgen is developing and commercializing the next generation of genomics tools to expand on the capabilities of spatially resolved transcriptomics.

Terry is a pioneer in the emerging Spatial Biology market, with a proven track record of driving exceptional growth across global life science organizations, including Bristol-Myers Squibb, Roche, Hologic, and PerkinElmer. In addition to his two decades of experience scaling and building multinational biopharma and diagnostic groups, he is also an expert in developing business strategies for novel, innovative products.

Join us for part 2 of our conversation with Terry, where we talk about his transition from Big Pharma to diagnostics, the challenges of moving into the diagnostics industry, and the contrasts between drug and diagnostic development processes. Terry also discusses his experience at Roche, his time with Akoya Biosciences after PerkinElmer, and his involvement in the M&A process while balancing multiple roles. Please enjoy my conversation with Terry Lo.
Find Our Guest, Terry Lo, at these links:

Find Our Host, Jon Chee, at these links:

Timestamps:
00:28 Intro
01:35 Leaving Bristol, joining Cytyc, and transitioning into International Strategy role
03:48 The contrasts between Diagnostics and Big Pharma
05:28 Drug development vs. diagnostics development processes
09:27 Moving to China and adapting to his role change from International Strategy to Managing Director
10:43 Adjusting to life in China with his pregnant wife
13:25 Moving back to the US and joining Roche Molecular in California
15:26 Transitioning to PerkinElmer and Terry’s intro to spatial biology
17:28 The challenges and triumphs in this new field
20:25 The challenges of regulatory agencies and reimbursement in Diagnostics and getting a product through the FDA
24:58 Merging with Akoya Biosciences after PerkinElmer to support Terry’s platform
26:51 Terry’s experience with M&A of Akoya by PerkinElmer, balancing multiple roles
29:13 Outro ​

Social & Website:

Topics Mentioned:
Drug development vs. diagnostics development https://www.ncbi.nlm.nih.gov/books/NBK235489/
How Biotech & Big Pharma Partner to Support R&D https://www.excedr.com/blog/how-biotech-partnerships-support-research
Regulatory and reimbursement impacts in Pharma https://www.ncbi.nlm.nih.gov/books/NBK234312/
Drug approval with FDA
The Biotech Startups Podcast is handcrafted by our friends over at: fame.so
  continue reading

76 episoder

Alla avsnitt

×
 
Loading …

VĂ€lkommen till Player FM

Player FM scannar webben för högkvalitativa podcasts för dig att njuta av nu direkt. Den Àr den bÀsta podcast-appen och den fungerar med Android, Iphone och webben. Bli medlem för att synka prenumerationer mellan enheter.

 

Snabbguide